Tumor–antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
暂无分享,去创建一个
[1] W. J. Harrison. The total cellularity of the bone marrow in man , 1962, Journal of clinical pathology.
[2] H Stein,et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[3] J. Taylor‐Papadimitriou,et al. MONOCLONAL ANTIBODIES TO EPITHELIAL MEMBRANE ANTIGEN AND HUMAN MILK FAT GLOBULE MUCIN DEFINE EPITOPES EXPRESSED ON OTHER MOLECULES , 1985, The Lancet.
[4] G. Riethmüller,et al. The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.
[5] S. Gay,et al. Immunolocalization of Gla proteins (osteocalcin) in rat tooth germs: comparison between indirect immunofluorescence, peroxidase-antiperoxidase, avidin-biotin-peroxidase complex, and avidin-biotin-gold complex with silver enhancement. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[6] W. Renmans,et al. Sensitive detection of immunogold-silver staining with darkfield and epi-polarization microscopy. , 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[7] F. Momburg,et al. Regulation and Functional Role of MHC Expression on Tumors , 1989 .
[8] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[9] L. Ries,et al. Leukemia following chemotherapy for breast cancer. , 1990, Cancer research.
[10] D. Slamon. Studies of the HER-2/neu proto-oncogene in human breast cancer. , 1990, Cancer investigation.
[11] R K Jain,et al. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.
[12] K. Pantel,et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. , 1991, Cancer research.
[13] K. Pantel,et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. , 1991, European journal of cancer.
[14] G. Riethmüller,et al. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers , 1992, Current Biology.
[15] G. Riethmüller,et al. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. , 1992 .
[16] J. Izbicki,et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.
[17] J. Izbicki,et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.
[18] R. Dillman,et al. Antibodies as cytotoxic therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Riethmüller,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.
[20] I. Fidler,et al. Modulation of the organ microenvironment for treatment of cancer metastasis. , 1995, Journal of the National Cancer Institute.
[21] H. Allgayer,et al. Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.
[22] S. Braun,et al. Biological characteristics of micrometastatic carcinoma cells in bone marrow. , 1996, Current topics in microbiology and immunology.
[23] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] F. Schildberg,et al. Comparative analyses of bone marrow micrometastases in breast and gastric cancer , 1996, International journal of cancer.
[25] R. Holle,et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[26] G. Hansson,et al. Distinct sub‐populations of carcinoma‐associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl‐Lewis a and sialyl‐Lewis x epitopes in the circulation of breast‐cancer patients , 1996, International journal of cancer.
[27] A. Scott,et al. Antibody-based immunological therapies. , 1997, Current opinion in immunology.
[28] H. Allgayer,et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. , 1997, Cancer research.
[29] B. Naume,et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. , 1997, Journal of hematotherapy.
[30] S. Braun,et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[31] A. van Dalen,et al. Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 Workshop , 1998, Tumor Biology.
[32] V. Reuter,et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.